These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33055159)

  • 1. The support of genetic evidence for cardiovascular risk induced by antineoplastic drugs.
    Cui H; Zuo S; Liu Z; Liu H; Wang J; You T; Zheng Z; Zhou Y; Qian X; Yao H; Xie L; Liu T; Sham PC; Yu Y; Li MJ
    Sci Adv; 2020 Oct; 6(42):. PubMed ID: 33055159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Therapeutics-Related Cardiac Dysfunction　- Insights From Bench and Bedside of Onco-Cardiology.
    Kadowaki H; Akazawa H; Ishida J; Komuro I
    Circ J; 2020 Aug; 84(9):1446-1453. PubMed ID: 32727978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drugs cardiotoxicity].
    Capilla E; Poyet R; Brocq FX; Pons F; Kerebel S; Jego C; Laurent P; Cellarier GR
    Presse Med; 2015 Oct; 44(10):995-1002. PubMed ID: 26153088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: A systematic review and meta-analysis of genotypes effect.
    Leong SL; Chaiyakunapruk N; Tassaneeyakul W; Arunmanakul P; Nathisuwan S; Lee SWH
    Int J Cardiol; 2019 Apr; 280():190-197. PubMed ID: 30594345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular complications of chemotherapy].
    Tovena DM; Inzoli A; Donato G; Gazzaniga P; Bianchessi C
    G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):165S-170S. PubMed ID: 23096398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of anthracycline cardiotoxicity.
    Mele D; Tocchetti CG; Pagliaro P; Madonna R; Novo G; Pepe A; Zito C; Maurea N; Spallarossa P
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S3-S11. PubMed ID: 27183523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular complications of cancer chemotherapy. The need for cardio-oncology.].
    Dolara A
    Recenti Prog Med; 2017 Jun; 108(6):261-264. PubMed ID: 28631773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
    Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
    CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.
    Chang HM; Moudgil R; Scarabelli T; Okwuosa TM; Yeh ETH
    J Am Coll Cardiol; 2017 Nov; 70(20):2536-2551. PubMed ID: 29145954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer drugs and the heart: importance and management.
    Suter TM; Ewer MS
    Eur Heart J; 2013 Apr; 34(15):1102-11. PubMed ID: 22789916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular effects of systemic cancer treatment.
    Senkus E; Jassem J
    Cancer Treat Rev; 2011 Jun; 37(4):300-11. PubMed ID: 21126826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial hypertension in patients under antineoplastic therapy: a systematic review.
    Katsi V; Magkas N; Georgiopoulos G; Athanasiadi E; Virdis A; Masi S; Kliridis P; Hatziyanni A; Tsioufis C; Tousoulis D
    J Hypertens; 2019 May; 37(5):884-901. PubMed ID: 30624368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
    Xu R; Wang Q
    J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer treatment-related cardiovascular disease: Current status and future research priorities.
    Nonaka M; Hosoda H; Uezono Y
    Biochem Pharmacol; 2021 Aug; 190():114599. PubMed ID: 33989656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of Cancer Patients with Cardiovascular Complications - Onco-Cardiology].
    Mukai M
    Gan To Kagaku Ryoho; 2016 Aug; 43(8):940-4. PubMed ID: 27539035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Future of Onco-Cardiology: We Are Not Just "Side Effect Hunters".
    Abe J; Martin JF; Yeh ET
    Circ Res; 2016 Sep; 119(8):896-9. PubMed ID: 27688305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular Complications of Cancer Chemotherapy.
    Cameron AC; Touyz RM; Lang NN
    Can J Cardiol; 2016 Jul; 32(7):852-62. PubMed ID: 26968393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology.
    Fatunde OA; Brown SA
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.
    Sandhu H; Maddock H
    Clin Sci (Lond); 2014 Mar; 126(6):377-400. PubMed ID: 24274966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
    Visscher H; Ross CJ; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR;
    Pediatr Blood Cancer; 2013 Aug; 60(8):1375-81. PubMed ID: 23441093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.